Healthcare can be complicated.
Your cardiology news shouldn’t be.

Join thousands of cardiology leaders today.

Cardiology Pharmaceuticals June 22, 2023

Agepha’s Lodoco FDA-Approved for CVD Inflammation June 22, 2023

Agepha Pharma’s Lodoco (colchicine) just became the first anti-inflammatory drug to land FDA approval for reducing cardiovascular event risks, marking a major milestone in the emerging field of CVD inflammation treatment.

Cardiology Pharmaceuticals June 20, 2023

NYU’s Atherosclerosis Inflammation Discovery June 20, 2023

NYU researchers discovered that AstraZeneca’s saracatinib - an investigational drug originally developed to treat cancer - could slow atherosclerosis progression by addressing inflammation that we know contributes to ASCVD and haven't figured out how to treat.

Cardiology Policy June 15, 2023

Glenfield Hospital’s Nurse-Performed TAVI Uproar June 15, 2023

Glenfield Hospital Cardiology, just outside Leicester in the UK, set cardiology channels ablaze earlier this week with a celebratory tweet announcing that one of its advanced nurse practitioners performed a whole TAVI procedure (aka TAVR in the U.S.) as the first operator.

Cardiology Pharmaceuticals June 12, 2023

Bitterroot Bio’s Cardio-Immunology Mission June 12, 2023

Bitterroot Bio emerged last week, announcing a massive $145M Series A round and an equally massive mission to “rewrite the practice of cardiology” through cardio-immunology therapeutics.

Cardiology Guidelines June 8, 2023

Questioning Antihypertensives for Older Patients June 8, 2023

When clinicians find that an older hospitalized patient has elevated blood pressure, their next step is often to initiate antihypertensive treatment, but a new JAMA Internal Medicine study suggests that many of these patients would be better off having their BPs left unmanaged.

Cardiology Pharmaceuticals June 5, 2023

Lexicon’s Lands Long-Awaited HF Approval June 5, 2023

Lexicon Pharmaceuticals’ Inpefa (sotagliflozin) just became the first FDA-approved dual SGLT2 / SGLT1 inhibitor for treating heart failure, landing a wide-ranging approval that could alter the HF treatment arena.

Remote Care June 1, 2023

UCSD’s Wearable Cardiac Ultrasound Milestone June 1, 2023

A team of UCSD scientists took a major step towards changing how, when, and where cardiac ultrasound exams are performed, unveiling the first fully integrated wearable ultrasound system intended for continuous heart monitoring.

Remote Care May 25, 2023

Remote Cardiac Monitoring Gains Momentum May 25, 2023

The last week featured two of the world’s largest heart failure and electrophysiology conferences, each driving a surge of new papers and studies suggesting that remote monitoring is moving to the forefront of both cardiology subspecialties.

Cardiology Pharmaceuticals May 22, 2023

SCOTUS Rules Against Amgen in PCSK9 Patent Dispute May 22, 2023

The U.S. Supreme Court ruled against Amgen in its PCSK9 inhibitor patent dispute with Sanofi and Regeneron that was intended to revive patents for Amgen’s cholesterol-lowering drug, Repatha.

Cardiology Pharmaceuticals May 18, 2023

Amarin Vascepa’s Coronary Physiology Improvements May 18, 2023

Amarin presented results from the latest study on its Vascepa CVD medication (icosapent ethyl, aka IPE), suggesting that IPE improves users' coronary physiology.

Artificial Intelligence May 15, 2023

Philips Expands into Echo AI with DiA Acquisition May 15, 2023

Philips took a major step towards automating and expanding access to echo ultrasound exams, acquiring echo AI startup DiA Imaging Analysis.

Cardiology Pharmaceuticals May 11, 2023

AstraZeneca’s Farxiga Lands Heart Failure FDA Extension May 11, 2023

AstraZeneca’s Farxiga (dapagliflozin) oral SGLT2 inhibitor just landed FDA approval for a far wider range of heart failure patients, now covering risk reduction among all adults with HF -- regardless of their left ventricular ejection fraction status.

Cardiology Pharmaceuticals May 8, 2023

Tirzepatide Delivers in SURMOUNT-2 May 8, 2023

Results from Eli Lilly’s SURMOUNT-2 trial are in, and they further confirmed that its GLP-1 agonist tirzepatide drives meaningful weight loss among obese or overweight adults with type 2 diabetes.

Preventive Cardiology May 4, 2023

Unraveling Depression’s CVD Link May 4, 2023

People with depression have up to 72% higher risks of developing cardiovascular disease, but there’s still many scientific blindspots regarding the links between depression and CVD. Two new studies added visibility to those blindspots, particularly related to prenatal depression and psychotherapy.

Cardiology Pharmaceuticals May 1, 2023

A Case for Antihypertensive Polypills May 1, 2023

A new JAMA Cardiology study suggests that many hypertension patients could benefit from beginning their treatment with “polypills” featuring a combination of three or four low-dose antihypertensives, rather than starting with one or two BP-lowering agents and escalating if they don’t prove effective.

Cardiology Practices April 27, 2023

Cardiovascular Associates Bolsters VBC Capabilities with NovoCardia Acquisition April 27, 2023

Private equity-backed and value-based care-focused cardiology group acquisitions have become an almost weekly occurrence in 2023, but Cardiovascular Associates of America’s (CVAUSA) acquisition of NovoCardia introduced a new telehealth-led angle to this trend.

Artificial Intelligence April 24, 2023

Toku Envisions Retail-Based Retinal CVD and Diabetes Screening April 24, 2023

Cardiovascular disease and diabetes screening might be headed to your neighborhood eyeglasses retailer, at least if retinal AI startup Toku Eyes and its heavyweight optical industry backers prove correct.

Artificial Intelligence April 20, 2023

Cardiology’s AI Optimization Opportunity April 20, 2023

Cardiology AI's downstream potential, delayed and early AF ablation outcomes, and plenty of other cardiology news.

Cardiology Pharmaceuticals April 17, 2023

The Potential of Personalized Hypertension Medicine April 17, 2023

A new study out of Sweden shows that people with hypertension can respond significantly better to some treatments than others, suggesting that hypertension treatment decisions might become far more personalized in the future.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!